Make an enquiry
Refer a patient
Patient Portal
HCP Logout

We noticed you are on our AU page. Want to switch regions? Choose from the options:

UK
ES
Make an enquiry
Refer a patient

We noticed you are on our AU page. Want to switch regions? Choose from the options:

UK
ES
Find a centre
Find a doctor
2024-08-28T05:40:27.049Z

ProsTACT-Global-203

ProsTACT-Global-203
Prostate cancer

A Multinational, Multicenter, Prospective, Randomized, Controlled, OpenLabel, Phase 2/3 Study of Lutetium Rosopatamab Tetraxetan plus Standard of Care vs. Standard of Care alone for Patients with PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously Treated Androgen Receptor Pathway Inhibition.

A Multinational, Multicenter, Prospective, Randomized, Controlled, OpenLabel, Phase 2/3 Study of Lutetium Rosopatamab Tetraxetan plus Standard of Care vs. Standard of Care alone for Patients with PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously Treated Androgen Receptor Pathway Inhibition.

Trial overview

Clinical Area

Theranostics

Disease / Condition

Prostate cancer

Study Phase

II-III

Trial Identifiers

NCT06520345 

 

https://clinicaltrials.gov/study/NCT06520345

GenesisCare Location(s)

GenesisCare Murdoch

GenesisCare Murdoch :::
Principal Investigator(s)

Dr Aviral Singh

 

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.